9
Participants
Start Date
March 28, 2019
Primary Completion Date
November 17, 2021
Study Completion Date
January 6, 2023
GLYCAR T cells
"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
Cytoxan
Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
Fludarabine
Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
Houston Methodist Hospital, Houston
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
The Methodist Hospital Research Institute
OTHER
Cancer Prevention Research Institute of Texas
OTHER
Baylor College of Medicine
OTHER